Work

306 Repurposing antiviral memory CD4 T cells to enhance tumor-specific CD8 T cell expansion for adoptive cell therapy

Year: 2026
Type: conference-abstract
Abstract: Background Adoptive cell therapy (ACT) for solid tumors is frequently limited by the inability to generate sufficient numbers of functional tumor-specific CD8 T cells during ex vivo manufacturing. Nanoparticle-based artificial antigen-presenting cells (aAPCs) provide a platform for antigen-specific T cell activation and expansion. We hypothesized that reactivation of pre-existing antiviral memory CD4 T cells using aAPCs could provide a clinically accessible source of Th1 help to improve tumor-specific CD8 T cell products for ACT.Methods Human peripheral blood CD4 and CD8 T cells were stimulated using aAPCs presenting MHC class II viral peptides and MHC class I tumor peptides. Virus-specific CD4 T cells were expanded using MHC II aAPCs and characterized by tetramer staining and phenotypic markers. Tumor-specific CD8 T cells recognizing the melanoma antigen MART-1 were expanded in the presence or absence of antiviral CD4 T cell help. Antigen-specific expansion was quantified by tetramer staining and total cell yield.Results MHC II aAPCs successfully expanded antigen-specific antiviral CD4 T cells from multiple human donors. Expanded tetramer-positive CD4 T cells displayed increased expression of CXCR3, CD154, and PD-1, consistent with an activated Th1-like phenotype. Co-culture of antiviral CD4 T cells with MART-1-specific CD8 T cells resulted in substantially greater CD8 expansion compared with CD8 stimulation alone. Across multiple donors, CD4 help increased both the frequency and absolute number of MART-1-specific tetramer-positive CD8 T cells, yielding up to an order-of-magnitude improvement in expansion. These findings demonstrate that antigen-specific antiviral CD4 T cells can provide functional helper signals that enhance generation of tumor-specific CD8 T cells.Conclusions Pre-existing antiviral memory CD4 T cells represent a readily accessible and clinically translatable source of helper activity for ACT manufacturing. Nanoparticle aAPCs presenting viral and tumor antigens enable coordinated activation of antiviral CD4 and tumor-specific CD8 T cells, resulting in enhanced expansion of therapeutic CD8 populations. Ongoing studies are evaluating the effects of CD4 help on CD8 functionality, persistence, and antitumor activity.
Language: English
Subfield: Immunology
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W7225142283
Cites:
Cited by:
Related to: 10